Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,809 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes Clear all
Completed Not applicable Interventional Results available

Omnipod 5 System Compared to Pump Therapy

NCT05409131
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Omnipod 5 System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Palo Alto, California • Santa Barbara, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)

NCT05422053
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
t:slim X2 insulin pump with Control-IQ technology 1.5
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Aurora, Colorado • Idaho Falls, Idaho • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Time Limited Eating in Type 1 Diabetes

NCT05031429
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Time Limited Eating
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 25 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

NCT02825251
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
472 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Encino, California • Fresno, California • Roseville, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 22, 2026, 5:16 AM EDT
Not yet recruiting Not applicable Interventional

Food is Medicine in Pediatric Patients With Diabetes

NCT07535502
View directory record Official record
Conditions
Type I Diabetes, Pediatrics, Food Insecurity
Interventions
Community Servings, PedsQL Survey, Nutrition Counseling, SDOH Survey
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
5 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study for HypoPals, a Mobile Health Program for Improving Hypoglycemia Management.

NCT05916131
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Basic Education, Hypoglycemia Symptom Detection Training, Education Plus
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Results available

Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes

NCT03020069
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CGMS Device, No Device
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
13 Years to 19 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Adolescent Investment In Diabetes Care

NCT04516694
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Financial incentive (gain), Financial incentive (loss)
Behavioral
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
12 Years to 18 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 22, 2026, 5:16 AM EDT
Not listed Phase 1Phase 2 Interventional

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

NCT01947569
View directory record Official record
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

NCT03638141
View directory record Official record
Conditions
Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2

NCT00574639
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Alprazolam, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 22, 2026, 5:16 AM EDT
Active, not recruiting Not applicable Interventional

Device Use Reimagined Through Education And Mentorship

NCT06546930
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
DREAM intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Davis, California • Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 22, 2026, 5:16 AM EDT
Terminated No phase listed Observational

Type 1 Diabetes and Eating Disorder Diurnal Glucose Patterns

NCT01390636
View directory record Official record
Conditions
Type I Diabetes Mellitus Without Complication, Eating Disorder
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
14 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

NCT01683266
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
82
States / cities
Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 22, 2026, 5:16 AM EDT
Completed No phase listed Observational

Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes

NCT02423434
View directory record Official record
Conditions
Diabetic Polyneuropathy, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes Complications
Interventions
Exposure: Corneal nerve fibre morphology by the CCM Procedure
Other
Lead sponsor
Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Other
Eligibility
18 Years and older
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

NCT04233034
View directory record Official record
Conditions
Type1 Diabetes
Interventions
HCL, verapamil 120mg tablet, non-HCL, placebo
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients

NCT02625636
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
SAR438544, placebo, r-glucagon
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Oct 22, 2026, 5:16 AM EDT
Completed No phase listed Observational

Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation

NCT02004964
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

NCT01441232
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
LX4211, Januvia®
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Early Phase 1 Interventional

Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin

NCT03400501
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Degludec, Insulin Glargine
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Not applicable Interventional

Home-Based Interventions for Adolescents With Type 1 Diabetes

NCT02243072
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Fit Families plus Standard Medical Care
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
10 Years to 17 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

NCT03439072
View directory record Official record
Conditions
Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
Interventions
G-Pen, Lilly Glucagon
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Chula Vista, California • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 22, 2026, 5:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skin Blood Flow in Patients With Type 1 Diabetes Mellitus Compared to Normal Controls

NCT01592539
View directory record Official record
Conditions
Type 1 Diabetes,, Bone
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 50 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 22, 2026, 5:16 AM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM

NCT02597400
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, HMS5552
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 22, 2026, 5:16 AM EDT